As the second quarter of 2026 draws to a close, the pharmaceutical industry finds itself at a critical juncture. With major players pivoting away from pandemic-era windfalls toward long-term growth engines, investor scrutiny has reached a fever pitch. For industry titans Gilead Sciences, Pfizer, and Merck & Co., the latest quarterly earnings reports serve as both a report card on recent multi-billion-dollar acquisition strategies and a forecast of their ability to weather upcoming patent cliffs and shifting market landscapes.
Gilead Sciences: The High-Stakes Gamble on HIV Dominance
Main Facts and Market Position
Gilead Sciences continues to walk a tightrope between its legacy as the undisputed leader in HIV care and its ambitious attempts to diversify into oncology and autoimmune disease. Having deployed tens of billions of dollars into aggressive dealmaking—including acquisitions of Arcellx and others—Gilead’s core identity remains tethered to its HIV franchise. In Q2 2026, the company reported $7.6 billion in total product sales, an 8% year-over-year increase that suggests operational resilience.
Chronology of Performance
The narrative surrounding Gilead this quarter is dominated by two primary products: the stalwarts Biktarvy and Descovy, and the newcomer, Yeztugo. Combined, the legacy HIV treatments generated $5.7 billion, handily surpassing Wall Street’s expectations. Yeztugo, the company’s twice-yearly injectable preventive shot, hit $232 million in sales. This performance has placed the drug firmly on track to meet Gilead’s internal $1 billion annual target. Consequently, the company has raised its full-year HIV growth guidance to 9%–10%, up from the previous 8% forecast.
Implications and Divergent Analyst Perspectives
The market reaction has been bifurcated. RBC Capital Markets analyst Brian Abrahams hailed the performance as a return to the “good old days,” noting that Gilead’s strong operational base provides a buffer against the inevitable market fragmentation caused by newer HIV treatment alternatives.
However, the enthusiasm is not universal. Leerink Partners analyst Daina Graybosch remains skeptical, pointing to “uncertain signals” regarding Yeztugo’s long-term trajectory. While Gilead’s data shows that over 70% of first-time Yeztugo users returned for their second injection—a retention rate the company describes as “well above” oral pill alternatives—critics argue this represents a cohort of highly motivated early adopters. As Gilead seeks to penetrate broader communities with historically lower PrEP usage, analysts warn that maintaining such high persistence rates may prove difficult.
Pfizer: A "Show Me" Story in the Wake of COVID-19
The Pivot from Pandemic Profits
Pfizer’s recent history is defined by the massive decline in demand for its COVID-19 portfolio, specifically the Comirnaty vaccine and Paxlovid antiviral. This revenue contraction has forced the company into a radical reinvention. Through a $43 billion acquisition of Seagen and a $10 billion investment in Metsera, Pfizer is aggressively pivoting toward oncology and the high-growth obesity drug market. Simultaneously, the company is executing a massive $6.7 billion cost-cutting initiative.
Supporting Data and Financial Health
Pfizer’s Q2 results exceeded expectations, prompting a $500 million increase in revenue guidance. This growth was bolstered by the contribution of Padcev (a legacy Seagen asset) and steady performers like Eliquis and Vyndamax. However, these successes are shadowed by significant headwinds: imminent patent expirations for key blockbusters and a $3.8 billion impairment charge following the failure of a Seagen lung cancer candidate in clinical trials. Furthermore, a $525 million write-down on a discontinued sickle cell drug underscores the inherent volatility of a heavy acquisition strategy.
Official Responses and Future Outlook
During the Q2 earnings call, Chief Scientific Officer Chris Boshoff emphasized the potential of mevrometostat, an experimental prostate cancer drug. Currently in a trio of Phase 3 trials, the drug is being positioned as a potential “breakthrough therapy” that could outperform the current standard of care, Xtandi.
The sentiment from Wall Street remains cautious. RBC analyst Trung Huynh summarized the prevailing mood, labeling Pfizer a "show me" company. The upcoming Phase 3 data for mevrometostat, expected in Q4, is widely seen as the definitive litmus test: it will determine whether Pfizer is successfully executing a long-term growth strategy or merely managing a prolonged period of corporate restructuring.
Merck & Co.: Balancing Keytruda’s Future and the PCSK9 Frontier
The Keytruda Conundrum
Merck & Co. faces the most significant challenge of any major pharma company: managing the eventual loss of exclusivity for Keytruda, the world’s top-selling drug. Despite this looming threat, the company maintains a bullish outlook, targeting $70 billion in annual sales. Its strategy relies on a combination of internal innovation—such as the subcutaneous formulation of Keytruda (Keytruda Qlex)—and strategic acquisitions like Prometheus Biosciences.
Chronology of Pipeline Successes and Stumbles
The company’s recent performance shows a mix of triumph and turbulence. Keytruda Qlex sales surged to $463 million in Q2, significantly outperforming estimates. Similarly, acquired assets like Welireg, Winrevair, and Ohtuvayre are meeting or exceeding financial projections.
However, the path forward is not without roadblocks. A key drug candidate acquired via the $11 billion Prometheus deal yielded mixed results in clinical trials, failing a crucial study and casting doubt on its future in Crohn’s disease. Furthermore, the launch of Lipfendra—a cholesterol-lowering pill targeting the PCSK9 protein—has been marked by a slow start.
Implications: The Long Road for Lipfendra
Merck’s approach to Lipfendra is characterized by deliberate, strategic pricing designed to capture market share from established injectables. CEO Rob Davis has been transparent with investors, noting that “it will take time to get access established” and that the drug will not be a “fast out of the gate” success.
While analysts like RBC’s Trung Huynh have characterized near-term sales of Lipfendra as “negligible,” others are more optimistic. Leerink’s Daina Graybosch anticipates that the drug will eventually gain faster uptake than previous PCSK9 inhibitors, potentially hitting $476 million by 2027. Ultimately, Merck’s ability to reach its $70 billion revenue goal depends on its capacity to nurture these early-stage blockbusters while navigating the clinical trial risks inherent in its diverse pipeline.
Comparative Analysis: Industry Trends and Strategic Takeaways
The earnings season reveals three distinct, yet interconnected, trends across the biopharmaceutical landscape:
- The "Retention" Metric as the New Benchmark: Companies are moving beyond simple revenue reporting to focus on patient persistence and real-world utility. Gilead’s focus on Yeztugo’s second-dose retention rate and Pfizer’s reliance on upcoming clinical readouts demonstrate that investors are looking for long-term "stickiness" in patient treatment rather than just initial adoption.
- Acquisition Integration Risk: The "buy-to-grow" model remains the dominant industry strategy, but it is proving increasingly expensive and volatile. Pfizer’s multi-billion-dollar write-downs and Merck’s mixed results from the Prometheus acquisition highlight the high probability of failure when integrating external assets into a core portfolio.
- Restructuring as a Default Mode: All three companies are fundamentally different entities than they were three years ago. Whether through Gilead’s diversification, Pfizer’s cost-cutting, or Merck’s post-Keytruda planning, the industry is in a permanent state of transformation.
Conclusion
As the second half of 2026 unfolds, the market is no longer satisfied with broad promises of growth. Investors are demanding granular proof—clinical trial successes, retention metrics, and evidence of market access. For Gilead, Pfizer, and Merck, the challenge is clear: they must demonstrate that their aggressive investments in new science can offset the vulnerabilities of their aging portfolios. The next two quarters will likely be the deciding factor in whether these companies can transition successfully into their next era of profitability.
About the Author
